BioCentury | Jul 28, 2020
Politics, Policy & Law

Biopharma industry accelerates attacks on Trump

Last week the White House invited Pfizer Chairman and CEO Albert Bourla to join a group of his peers at the White House Tuesday to discuss drug pricing with President Donald Trump. Instead of traveling...
BioCentury | Jul 7, 2020
Product Development

BD’s launch will be a test for the utility of COVID-19 antigen testing

The launch and scale-up of BD’s SARS-CoV-2 rapid antigen test will help reveal whether the modality strikes the right balance of speed, accessibility and reliability needed to fill critical holes in COVID-19 testing infrastructure. Becton...
BioCentury | Jun 19, 2020
Product Development

T cell tests aim for broader picture of COVID-19 immunity

While the COVID-19 testing conversation has centered on assays for antiviral antibodies or the virus itself, at least two companies think T cell tests could catch patients the other methods miss. T cell tests could...
BioCentury | Jun 13, 2020

Daily Chart: AbbVie’s deals by disease and type

In the seven years since its split from Abbott, AbbVie has entered at least 38 disclosed therapeutics deals, including 20 in cancer. Within cancer, AbbVie has engaged in about twice as many licensing and acquisition...
BioCentury | Jun 12, 2020

Reata rebound

Shares of Reata Pharmaceuticals Inc. (NASDAQ:RETA) rose $36.76 (28%) to $167.68 on Thursday following a $350 million investment from Blackstone Life Sciences. The deal, which includes a $50 million equity investment and a $300 million...
BioCentury | Jun 11, 2020

In course correction, AbbVie steers toward innovation with Genmab deal

AbbVie’s Genmab deal gives it a ticket to one of the hottest modality spaces, albeit as a latecomer. The pharma gains bispecific antibodies to add to its ADCs and standard mAbs, extending its tool kit...
BioCentury | Jun 11, 2020
Product Development

Emerging COVID-19 serology tests aim for neutralizing antibodies

The next wave of serology tests from big diagnostic players could get closer to telling people whether they are protected from COVID-19 by homing in on the antibodies most likely to block viral entry into...
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

iTeos Therapeutics S.A. made several hires Tuesday, including Matthew Gall as CFO and Yvonne McGrath as VP of R&D. Gall was SVP of corporate development at Sarepta Therapeutics Inc. (NASDAQ:SRPT); McGrath was CSO of Complix...
BioCentury | May 20, 2020
Product Development

Roche, Abbott say sample collection differences hampered COVID-19 sensitivity in independent studies

Roche and Abbott each responded to independent reports that their COVID-19 tests are less sensitive than claimed with additional validation data supporting stronger performance and statements attributing discrepancies to sampling protocols. Both companies pointed to...
BioCentury | May 14, 2020
Product Development

New scrutiny prompts withdrawal, re-evaluation of two rapid COVID-19 tests

A serological test withdrawal from BD and BioMedomics and reports of false negatives by Abbott’s point-of-care diagnostic highlight the need for regulatory oversight and independent validation in responses to the pandemic. FDA’s May 4 update...
Items per page:
1 - 10 of 4147